Evidence map›Paper›PMID 41805173›Full record

ArticleMicrobiology spectrum2026

Analytical and clinical evaluation of the Alinity m Resp-4-Plex assay in comparison to two singleplex SARS-CoV-2 assays and one multiplex respiratory assay.

Robert Ehret, Malik Prentice, Birgit Reinhardt, Martin Obermeier

Abstract readComparative StudyEvaluation Study
In one paragraph

Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Robert EhretMedical Center for Infectious Diseases Berlin, Berlin, Germany.ORCID 0000-0001-6960-0141
Malik PrenticeMedical Center for Infectious Diseases Berlin, Berlin, Germany.
Birgit ReinhardtAbbott GmbH, Wiesbaden, Germany.ORCID 0009-0007-7045-1105
Martin ObermeierMedical Center for Infectious Diseases Berlin, Berlin, Germany.ORCID 0000-0003-2511-9553

Funding

Abbott | Abbott Germany (Abbott GmbH)
6 · The paper itself

Abstract

After transition to the endemic phase of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, multiplex molecular assays detecting SARS-CoV-2, influenza A (FluA) and B (FluB), and respiratory syncytial virus (RSV) are key to following international monitoring guidance, especially in future outbreak situations. In the present study, the analytical and clinical performance of the Alinity m Resp-4-Plex assay ("Alin4Plex") was evaluated in comparison to those of three other assays: Alinity m SARS-CoV-2 ("AlinSARS"), RealTi

Indexed as

COVID-19SARS-CoV-2HumansInfluenza A virusInfluenza B virusInfluenza, HumanMultiplex Polymerase Chain ReactionRespiratory Syncytial Virus InfectionsSensitivity and SpecificityAlinity minfluenza Ainfluenza Breal-time PCRRSVSARS-CoV-2

Identifiers

PMID41805173
PMCPMC13055274

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.